### Takeda CEO Transition: Julie Kim Takes Over June 2026
Christophe Weber will be succeeded by **Julie Kim** as CEO in June 2026, ending a 12-year tenure. Major organizational restructuring effective April 1, 2026, includes a new International Business Unit, Strategy & Portfolio Development group, and Tran
- **Patient Finder impact:** Weber was a warm direct contact. Julie Kim's priorities and openness to digital health partnerships are unknown. Window to engage Weber is closing fast (before June). New IBU leader Giles Platford and incoming CEO Kim sho
- Sources: [Takeda newsroom](https://www.takeda.com/newsroom/newsreleases/2026/changes-to-organizational-structure-and-executive-leadership-team-for-fy2026/), [ContractPharma](https://www.contractpharma.com/breaking-news/takeda-reshapes-leadership-cr
### UCB + Citizen Health AI Partnership for Patient Finding
UCB signed a multi-year AI partnership with **Citizen Health** (Dec 2025) targeting epilepsy and rare diseases using patient data for drug development. UCB also investing $5B in US biologics manufacturing and BIMZELX coverage reached 100K+ patients.
- **Patient Finder impact:** UCB is actively investing in AI-driven patient identification -- directly adjacent to Patient Finder's value prop. This is both a competitive signal (they're building in-house capability via Citizen Health) and an opportu
- Sources: [BioSpace](https://www.biospace.com/press-releases/citizen-health-joins-forces-with-ucb-to-accelerate-drug-development-across-epilepsy-and-rare-diseases), [UCB newsroom](https://www.ucb.com/newsroom/press-releases/article/innovation-and-ex